Company Filing History:
Years Active: 2019
Title: Innovations in Diabetes Treatment by Feng-Yee Chang
Introduction
Feng-Yee Chang is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of diabetes treatment through his innovative research and development.
Latest Patents
Feng-Yee Chang holds a patent titled "Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same." This invention relates to the treatment of diabetes using toll-like receptor 4 (TLR-4) modulators. Specifically, it provides an isolated peptide from pneumolysin (PLY peptide) that is effective in treating diabetes. The PLY peptide acts as a TLR-4 antagonist, making it useful in treating diseases associated with TLR-4 activation. This groundbreaking work highlights the potential of TLR-4 antagonists in diabetes management.
Career Highlights
Feng-Yee Chang is associated with Kemyth Biotech Co., Ltd., where he continues to advance his research in biotechnology and pharmaceuticals. His work has garnered attention for its innovative approach to addressing diabetes, a condition affecting millions worldwide.
Collaborations
Feng-Yee Chang collaborates with talented individuals in his field, including Leung-Kei Siu and Pele Choi-Sing Chong. Their combined expertise contributes to the ongoing development of effective treatments for diabetes.
Conclusion
Feng-Yee Chang's contributions to diabetes treatment through his innovative patent demonstrate the importance of research in improving health outcomes. His work continues to inspire advancements in medical science.